The FDA has finalized label revisions for both single ingredient and combination long-acting beta-agonist-containing respiratory medications for the treatment of asthma. This action follows the ...

Company: Sepracor Pharmacologic class: Bronchodilator (long-acting beta2-agonist) Active ingredient: Arformoterol 15 µg/2 mL; solution for inhalation ...

Long-acting B-agonist (LABA) monotherapy among patients with asthma is rare. Of those with continued LABA monotherapy, most had missed opportunities for therapy change or education.

The Safety of Long‐Acting Beta‐Agonists and the Development of Combination Therapies for Asthma and COPD, Advances in Combination Therapy for Asthma and COPD, (102-134), (2012). https://doi ...

Long-acting beta-agonists can be used indefinitely. There is no cutoff in regard to duration. Thus, patients can be on a long-acting beta-agonist for decades if needed.

A study shows a lower mortality rate in older patients with chronic obstructive pulmonary disease initially prescribed long-acting beta-agonists vs patients who received a long-acting anticholinergic.

Long-acting beta agonists (LABAs) were associated with increased risk of asthma-related death, intubation, and hospitalization in a recent meta-analysis of individual patient data conducted by the ...

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments.

Black adults with asthma treated with long-acting beta-agonists plus inhaled corticosteroids demonstrated no improvement in time to asthma exacerbation compared with those who received tiotropium ...

This "Long Acting Beta Agonist Market" Report provides detailed information regarding factors influencing the growth of the market, such as drivers, restraints, opportunities, and challenges.